GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -38,647 | -37,177 | -7,299 | -4,510 | -259,186 |
| Depreciation Amortization | 509 | 461 | 341 | 164 | 9,746 |
| Accounts payable and accrued liabilities | 3,154 | N/A | N/A | N/A | N/A |
| Other Working Capital | 2,938 | 1,107 | 34 | 820 | 111 |
| Other Operating Activity | 28,387 | 32,435 | 4,876 | 2,565 | 238,652 |
| Operating Cash Flow | $-3,659 | $-3,174 | $-2,048 | $-961 | $-10,677 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 200 | 200 | N/A | N/A | -36 |
| Investing Cash Flow | $200 | $200 | $0 | $N/A | $-36 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 3,527 | 3,327 | 2,352 | 1,052 | 15,145 |
| Debt Repayment | -100 | -100 | -100 | -100 | -4,415 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -533 |
| Financing Cash Flow | $3,427 | $3,227 | $2,252 | $952 | $10,197 |
| Beginning Cash Position | 60 | 60 | 60 | 60 | 576 |
| End Cash Position | 28 | 313 | 264 | 51 | 60 |
| Net Cash Flow | $-32 | $253 | $204 | $-9 | $-516 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,659 | -3,174 | -2,048 | -961 | -10,677 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -36 |
| Free Cash Flow | -3,659 | -3,174 | -2,048 | -961 | -10,713 |